Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durability

BACKGROUND: Bimekizumab (BKZ), an IL-17A and IL-17F inhibitor, has demonstrated a rapid and high level of complete skin clearance in patients with psoriasis and complete normalization of the transcriptional signature of lesional skin after 8 weeks. OBJECTIVE: We sought to assess the durability of initial clinical response to BKZ for up to 4 years and investigate molecular mechanisms leading to the observed response. METHODS: Clinical data were pooled from 3 1-year phase 3 feeder studies (BE VIVID, BE READY, and BE SURE) and their 3-year open-label extension (BE BRIGHT). Transcriptomic analyses were conducted on 3 independent single-cell RNA-sequencing data sets from lesional psoriasis biopsies and bulk RNA-sequencing data from a phase 2a study. RESULTS: gene signature, was demonstrated in bulk transcriptomic analyses after 8 weeks of treatment (2 BKZ doses). CONCLUSIONS: cells.